Rapid Therapeutic Science Laboratories, Inc. (RTSL)

RTSL Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2020	FY 2019
Period Ending	Jun 30, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Mar 31, 2020	Mar 31, 2019
Revenue	-	-	0	0.14	0.01	-
Revenue Growth (YoY)	-	-	-99.62%	1432.50%	-	-
Cost of Revenue	-	-	0	0.03	0.01	-
Gross Profit	-	-	0	0.11	0	-
Selling, General & Admin	0.52	1.24	2.14	2.25	0.4	0.17
Operating Expenses	0.47	1.26	2.18	2.35	0.43	0.17
Operating Income	-0.47	-1.26	-2.18	-2.24	-0.43	-0.17
Interest Expense	-0.59	-1.9	-1.32	-0.12	-0.19	-0.18
Other Non Operating Income (Expenses)	1.11	1.36	0.63	-	-	-
EBT Excluding Unusual Items	0.06	-1.79	-2.87	-2.36	-0.62	-0.35
Other Unusual Items	-	-	-	-	-	0
Pretax Income	0.06	-1.79	-2.87	-2.36	-0.62	-0.35
Net Income	0.06	-1.79	-2.87	-2.36	-0.62	-0.35
Net Income to Common	0.06	-1.79	-2.87	-2.36	-0.62	-0.35
Shares Outstanding (Basic)	8	8	8	7	2	0
Shares Outstanding (Diluted)	8	8	8	7	2	0
Shares Change (YoY)	2.65%	1.54%	14.77%	176.87%	4885.43%	-51.18%
EPS (Basic)	0.01	-0.23	-0.38	-0.36	-0.26	-7.24
EPS (Diluted)	0.01	-0.23	-0.38	-0.36	-0.26	-7.24
Free Cash Flow	-0.25	-1.19	-2.5	-1.99	-0.19	-0.11
Free Cash Flow Per Share	-0.03	-0.15	-0.33	-0.30	-0.08	-2.21
Gross Margin	-	-	62.55%	81.04%	21.71%	-
Operating Margin	-	-	-407471.54%	-1600.35%	-4737.97%	-
Profit Margin	-	-	-537056.74%	-1687.39%	-6834.27%	-
Free Cash Flow Margin	-	-	-468476.03%	-1417.65%	-2084.95%	-
EBITDA	-0.44	-1.24	-2.14	-2.13	-0.4	-0.15
D&A For EBITDA	0.02	0.02	0.03	0.11	0.04	0.02
EBIT	-0.47	-1.26	-2.18	-2.24	-0.43	-0.17

Updated Aug 14, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.